Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]

被引:0
|
作者
Fu, Liang [1 ]
Xiong, Juan [2 ]
Wang, Haibo [3 ]
Zhang, Peize [1 ]
Yang, Qianting [1 ]
Cai, Yi [4 ]
Wang, Wenfei [1 ,4 ]
Sun, Feng [5 ]
Zhang, Xilin [6 ]
Wang, Zhaoqin [1 ]
Chen, Xinchun [4 ]
Zhang, Wenhong [5 ]
Deng, Guofang [1 ]
机构
[1] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis Shenzhen, Div Pulm Dis Dept 2,Shenzhen Clin Res Ctr TB, 29 Bulan Rd, Shenzhen 518112, Peoples R China
[2] Shenzhen Univ, Hlth Sci Ctr, 3688 Nanhai Ave, Shenzhen 518060, Peoples R China
[3] Peking Univ First Hosp, Peking Univ Clin Res Inst, Xueyuan Rd 38, Beijing 100191, Peoples R China
[4] Shenzhen Univ, Dept Pathogen Biol, Guangdong Key Lab Reg Immun & Dis, Sch Med, 1066 Xueyuan Ave, Shenzhen 518060, Peoples R China
[5] Fudan Univ, Huashan Hosp, Natl Med Ctr Infect Dis, Dept Infect Dis,Shanghai Key Lab Infectious Dis &, 12 Urumqi Middle Rd, Shanghai 200040, Peoples R China
[6] Fourth Peoples Hosp Foshan, TB Prevent & Control Dept, 106 Jinlannan Rd, Foshan 528000, Peoples R China
关键词
Multidrug-resistant; Tuberculosis; Efficacy; Safety; Trial; OUTCOMES;
D O I
10.1186/s12879-023-08644-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
IntroductionThe urgent need for new treatments for multidrug-resistant tuberculosis (MDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is evident. However, the classic randomized controlled trial (RCT) approach faces ethical and practical constraints, making alternative research designs and treatment strategies necessary, such as single-arm trials and host-directed therapies (HDTs).MethodsOur study adopts a randomized withdrawal trial design for MDR-TB to maximize resource allocation and better mimic real-world conditions. Patients' treatment regimens are initially based on drug resistance profiles and patient's preference, and later, treatment-responsive cases are randomized to different treatment durations. Alongside, a single-arm trial is being conducted to evaluate the potential of sulfasalazine (SASP) as an HDT for pre-XDR-TB, as well as another short-course regimen without HDT for pre-XDR-TB. Both approaches account for the limitations in second-line anti-TB drug resistance testing in various regions.DiscussionAlthough our study designs may lack the internal validity commonly associated with RCTs, they offer advantages in external validity, feasibility, and ethical appropriateness. These designs align with real-world clinical settings and also open doors for exploring alternative treatments like SASP for tackling drug-resistant TB forms. Ultimately, our research aims to strike a balance between scientific rigor and practical utility, offering valuable insights into treating MDR-TB and pre-XDR-TB in a challenging global health landscape. In summary, our study employs innovative trial designs and treatment strategies to address the complexities of treating drug-resistant TB, fulfilling a critical gap between ideal clinical trials and the reality of constrained resources and ethical considerations.Trail registrationChictr.org.cn, ChiCTR2100045930. Registered on April 29, 2021.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]
    Liang Fu
    Juan Xiong
    Haibo Wang
    Peize Zhang
    Qianting Yang
    Yi Cai
    Wenfei Wang
    Feng Sun
    Xilin Zhang
    Zhaoqin Wang
    Xinchun Chen
    Wenhong Zhang
    Guofang Deng
    BMC Infectious Diseases, 23
  • [2] Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan
    Rashitov, Makhmujan
    Franke, Molly F.
    Trevisi, Letizia
    Bekbolatova, Gulzhanat
    Shalimova, Julia
    Eshmetov, Gafurzhan
    Bektasov, Sagit
    LaHood, Allison
    Arlyapova, Nataliya
    Osso, Elna
    Yedilbayev, Askar
    Korotych, Oleksandr
    Ciobanu, Anisoara
    Skrahina, Alena
    Mitnick, Carole D.
    Seung, Kwonjune J.
    Algozhin, Yerkebulan
    Rich, Michael L.
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (04) : 1046 - 1053
  • [3] An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)
    Esmail, Aliasgar
    Oelofse, Suzette
    Lombard, Carl
    Perumal, Rubeshan
    Mbuthini, Linda
    Mahomed, Akhter Goolam
    Variava, Ebrahim
    Black, John
    Oluboyo, Patrick
    Gwentshu, Nelile
    Ngam, Eric
    Ackerman, Tertius
    Marais, Linde
    Mottay, Lynelle
    Meier, Stuart
    Pooran, Anil
    Tomasicchio, Michele
    Te Riele, Julian
    Derendinger, Brigitta
    Ndjeka, Norbert
    Maartens, Gary
    Warren, Robin
    Martinson, Neil
    Dheda, Keertan
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (10) : 1214 - 1227
  • [4] New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China
    Jing, Wei
    Wang, Qingfeng
    Wang, Jun
    Ma, Liping
    Huang, Mailing
    Wang, Jing
    Du, Yadong
    Cai, Baoyun
    Shi, Wenhui
    Li, Qi
    Li, Xuelian
    Chu, Naihui
    Nie, Wenjuan
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (02):
  • [5] Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial
    Snobre, Jihad
    Gasana, Joel
    Ngabonziza, Jean Claude Semuto
    Cuella-Martin, Isabel
    Rigouts, Leen
    Jacobs, Bart Karl
    de Viron, Emeline
    Herssens, Natacha
    Ntihumby, Jean Baptiste
    Klibazayre, Annualithe
    Ndayishimiye, Clement
    Van Deun, Armand
    Affolabi, Dissou
    Merle, Corinne S.
    Muvunyi, Claude
    Sturkenboom, Marieke G. G.
    Migambi, Patrick
    de Jong, Bouke C.
    Mucyo, Yves
    Decroo, Tom
    BMJ OPEN, 2024, 14 (07):
  • [6] An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial
    Tara C. Bouton
    Patrick P. J. Phillips
    Carole D. Mitnick
    Charles A. Peloquin
    Kathleen Eisenach
    Ramonde F. Patientia
    Leonid Lecca
    Eduardo Gotuzzo
    Neel R. Gandhi
    Donna Butler
    Andreas H. Diacon
    Bruno Martel
    Juan Santillan
    Kathleen Robergeau Hunt
    Dante Vargas
    Florian von Groote-Bidlingmaier
    Carlos Seas
    Nancy Dianis
    Antonio Moreno-Martinez
    C. Robert Horsburgh
    Trials, 18
  • [7] An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial
    Bouton, Tara C.
    Phillips, Patrick P. J.
    Mitnick, Carole D.
    Peloquin, Charles A.
    Eisenach, Kathleen
    Patientia, Ramonde F.
    Lecca, Leonid
    Gotuzzo, Eduardo
    Gandhi, Neel R.
    Butler, Donna
    Diacon, Andreas H.
    Martel, Bruno
    Santillan, Juan
    Hunt, Kathleen Robergeau
    Vargas, Dante
    von Groote-Bidlingmaier, Florian
    Seas, Carlos
    Dianis, Nancy
    Moreno-Martinez, Antonio
    Horsburgh, C. Robert, Jr.
    TRIALS, 2017, 18
  • [8] Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study
    Sun, Wen-Wen
    Yang, Ming
    Chen, Xiao-Hong
    Fan, Li-Chao
    Wu, Hao-Yu
    Zhang, Shao-Jun
    Chen, Yu
    Fan, Lin
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (04) : 219 - 227
  • [9] A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT
    Gao, Jingtao
    Gao, Mengqiu
    Du, Jian
    Pang, Yu
    Mao, Gary
    Lounis, Nacer
    Bakare, Nyasha
    Jiang, Yanxin
    Zhan, Ying
    Liu, Yuhong
    Li, Liang
    TRIALS, 2024, 25 (01)
  • [10] A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT
    Jingtao Gao
    Mengqiu Gao
    Jian Du
    Yu Pang
    Gary Mao
    Nacer Lounis
    Nyasha Bakare
    Yanxin Jiang
    Ying Zhan
    Yuhong Liu
    Liang Li
    Trials, 25